Abstract
Introduction
Until a few years ago, the standard therapy of welldifferentiated thyroid cancer (DTC) consisted of total or near total thyroidectomy followed by radioiodine (RAI) remnant ablation (RRA) and TSH suppressive levothyroxine (LT4) therapy [1] . The rationale for RRA included, and still includes, three major purposes: (a) the therapeutic purpose related to the irradiation of any neoplastic microfocus that can be present in about 50% of the thyroid remnant, especially in the case of papillary thyroid carci-noma (PTC); (b) the diagnostic purpose due to the possibility to perform a post-RRA whole-body scan (ptWBS) to identify additional sites of disease not identified before the RRA [2] [3] [4] ; and (c) the facilitator purpose because the ablation of residual normal thyroid tissue, commonly producing thyroglobulin (Tg), makes serum Tg measurements much more sensitive and predictive of recurrent or persistent disease.
In recent years, there has been a trend to reduce the use of RRA to limit the potential secondary side effects, particularly in patients with low-risk (LR) and intermediaterisk (IR) DTC, even if these effects are negligible for RAI activities < 100 mCi [5] [6] [7] . Nowadays, there is a general agreement that LR DTC should not be submitted to RRA [8, 9] since a significant increase in disease-free survival or decrease in mortality has been demonstrated in these patients [10] [11] [12] [13] [14] . On the opposite, the use of RRA, usually with high activities of 131 I, is recommended for the management of high-risk patients in whom this procedure has shown a positive impact on recurrence and survival [15, 16] . A selective use of RRA is proposed for the IR patients taking into account the level of risk of recurrence as well as the values of postoperative serum Tg and neck ultrasound (US) [17, 18] .
Despite the evidence of a limited therapeutic role of RRA in LR and IR DTC, to our knowledge, no studies on the benefits of the diagnostic role of ptWBS have been reported so far. Recently, we have published a study showing that only 1.3% of the LR and IR DTC patients showed a positive ptWBS when treated with 30 mCi and after recombinant human TSH (rhTSH) stimulation [18] . One criticism to this study could be that the sensitivity of the ptWBS after rhTSH might be much lower than after the stimulus of an elevated endogenous TSH obtained after LT4 withdrawal. The main objective of the present study was to evaluate the diagnostic role of ptWBS performed after RRA in LR and IR DTC patients prepared with LT4 withdrawal and, as a secondary objective, to verify how much the derived information could change the therapeutic strategies for these patients.
Patients and Methods

Study Groups
We analyzed the data of 545 consecutive patients (410 females [75.2%], 135 males [24.8%]) with LR (n = 345) or IR (n = 200) DTC treated with total thyroidectomy and referred to the Department of Endocrinology of Pisa for RRA during the year 2006. According to TNM and the American Thyroid Association guidelines for thyroid cancer management [8, 19] , LR consisted of T1-2mN0/xM0/x patients, and IR included T1-3N1Mx and T3N0Mx patients.
The mean age at diagnosis was 43.3 ± 13.4 years, with a median of 43.5 years. A total of 527 (96.7%) patients had PTC, and 18 (3.3%) had follicular thyroid cancer. Because the use of recombinant TSH was not yet part of clinical practice, all patients were treated for hypothyroidism obtained with LT4 withdrawal. According to our standard of care for LR and IR DTC patients, everybody was treated with a "low" activity of 30 mCi of 131 I (1,110 MBq) followed by ptWBS. Neck US, serum Tg, thyroid hormone measurements, and urinary iodine secretion were performed in all patients.
Biochemical Tests
All biochemical tests were conducted in the same laboratory of the Department of Endocrinology in Pisa. Serum Tg was measured using an immunometric assay (Immulite 2000 Tg; Diagnostic Products Corporation, Los Angeles, CA, USA) with a functional sensitivity of 0.9 ng/mL. TSH measurement was performed using an ultrasensitive immunochemiluminescent assay method (Immulite 2000 TSH; Diagnostic Products Corporation).
To avoid misinterpretation of Tg measurements, all patients were screened for circulating anti-Tg antibodies, using an immunofluorimetric method (AIA-Pack TgAb; Tosoh Corporation, Tokyo, Japan; normal range: 0-30 U/mL). Urinary iodine content was measured with the UV irradiation method employing an automated autoanalyzer (Bran-Luebbe S.P.A., Gallarate, Italy) [20] .
Neck US
US was performed using a color doppler apparatus (AU 590 Asynchronous; Esaote Biomediva, Florence, Italy) in all patients before RRA. The thyroid bed and central, laterocervical and supraclavear node compartments were evaluated for the presence of suspicious disease recurrence or persistence. In suspicious lymph node metastases, a fine-needle aspiration biopsy with Tg measurement in the needle washout was performed.
I-ptWBS
The ptWBS was performed using a dual-head large field-ofview gamma camera (Philips Axis; Picker International, Inc., Highlands Heights, OH, USA) with a 6/8-inch-thick crystal and equipped with high-energy high-resolution collimators. The ptWBS was performed 5-10 days after the 131 I treatment on the basis of a 50 µCi thyroid bed RAI 24-h uptake (New Atomlab 950; Biodex Medical System, Urbino, Italy).
In all patients, a low activity of 131 I (30 mCi) was administered providing that the TSH value was > 30 µU/mL and urinary iodine content < 300 mcg/L. 
Statistical Analysis
The statistical analysis of data was performed by Mann-Whitney U and χ 2 tests using a computer program Statview 4.5 software (Abacus Concepts Inc., Berkley, CA, USA). The results were considered statistically significant if p < 0.05.
Results
ptWBS Findings
The thyroid remnant was documented in all patients at ptWBS. In addition to this finding, the ptWBS showed the presence of further areas of 131 I uptake in 16/545 patients (2.9%; F = 11 and M = 5). According to the level of risk of recurrence, 5 patients were classified as LR (2.1%) and 11 as IR (5.5%; p = ns).
The histology was PTC in all 16 cases, 6 of whom showed a more aggressive variant (2 tall cells, 1 follicular with solid areas, 1 follicular with tall cells, 1 follicular with oxyphil areas, and 1 poorly differentiated papillary). As shown in Table 1 Table 2 .
Correlation between Serum Tg and Metastases
When considering the subgroup with metastases, the mean value of serum Tg off LT4 at the time of ablation, which can be considered the postsurgical control, was 115.4 ± 123.2 ng/mL in the LR group (range: 2.4-300 ng/ mL; median: 97) and 200.7 ± 250.9 ng/mL in the IR group (range: 0-733 ng/mL; median: 60) with no statistically significant differences between the two groups. At variance, the mean and median values of serum Tg in a subgroup of patients with only thyroid remnant (i.e., 230/529) were 11.1 and 7 ng/mL, respectively. No significant correlation was found between serum Tg values and metastatic lesions detected by ptWBS. Three out of 4 cases with distant metastases had a serum Tg value > 10 ng/mL (Fig. 1) .
Outcome
At the end of follow-up (mean 7.8 years), 8/16 patients with a positive ptWBS were free of disease (3 LR, 5 IR), whereas the other 8 had persistent disease (2 LR, 6 IR), without any difference of outcome according to the original level of risk (Fig. 2, panel A) . Of the 8 cases with persistent disease, 4 had "biochemical" disease and 4 had "structural" disease (2 lymph nodes, 1 mediastinum, and 1 bone). The 8 cases that became free of disease during follow-up obtained this result after one single course of 131 I in 3 cases (2 LR, 1 IR), after surgical treatment in 1 case (IR), and after several 131 I courses in the last 4 cases (1 LR, 3 IR). The outcome of these patients was independent from the original level of risk (Fig. 2, panel B) .
Discussion
The American Joint Committee on the Cancer TNM Staging System is currently the most accepted staging system for DTC patients to predict the risk of death [8] . However, the AJCC/TNM risk of mortality staging system does not adequately predict the risk of recurrences. Thus, the 2009 ATA Initial Stratification System proposed 3 disease recurrence risk categories, low, intermediate and high, that were validated in several recent retrospective studies [11, 12, 19] . In addition, this method was in accordance with the evidence that the death rates in both LR and IR DTC patients are extremely low [13, 14] .
Today, clinicians are faced with a growing number of patients with LR and IR DTC, and there is a need for safe, efficient, and cost-effective management strategies, avoiding overtreatment, and preserving the quality of life. In particular, despite the fact that RRA has traditionally been one of the cornerstones of DTC treatment, the decision to use RRA in LR and IR patients is more and more controversial [21] .
Currently, there is no evidence of a clinical benefit in terms of reducing recurrences and prolonging survival secondary to RRA in LR and IR DTC patients. However, no studies have been published on the diagnostic role of RRA, which is related to the higher sensitivity of ptWBS in finding metastases not detected by other imaging techniques. We have recently published a series of LR and IR DTC in which the ptWBS detected only 1.3% (7/505) of the cases with distant metastases that, without the administration of RRA, likely would have been diagnosed much later. These patients were prepared with rhTSH for RRA, and some concerns about a lower sensitivity of the ptWBS because of this type of preparation have arisen.
In the present study, we analyzed the ptWBS results in 345 LR patients and 200 IR patients treated with 1,110 MBq of 131 I for RRA after LT4 withdrawal. The ptWBS played a diagnostic role in only 2.9% of the patients after RRA because it identified local and/or distant metastases, with no difference between LR and IR cases. In addition to the thyroid remnant that was present in all cases, ptWBS showed the presence of laterocervical lymph node metastases in 11/16 cases, mediastinal lymph node metastases in 1/16 cases, lung metastases in 3/16 cases, and bone metastases in 1/16 cases.
As far as lymph node metastases are concerned, 10/11 were also detected by neck US and confirmed by cytology examination. This evidence limited the diagnostic role of ptWBS to 6/545 (1.1%) cases, which is superimposed to the 1.3% that we found in the series of LR and IR patients prepared with rhTSH for RRA [18] . Moreover, this finding confirmed the excellent accuracy of neck US for the study of neck metastatic lesions [22] . Of the remaining 6 cases, 1 had laterocervical lymph node metastasis, 1 had mediastinal lymph node metastasis, 3 had lung metastases, and 1 had bone lesion metastasis that could not be found without the use of ptWBS. It is of interest that among these 6 cases, 3 were LR patients, 3 were IR patients, and only 1 showed a more aggressive histological variant. This finding greatly reduces the prognostic significance of the level of risk in predicting the presence of metastatic lesions out of the neck.
Despite the absence of a specific correlation between serum Tg levels and distant metastases, 2/3 cases with lung metastases (1 LR and 1 IR cases) had a post-thyroidectomy serum Tg > 100 ng/mL that could create at least the doubt of metastatic disease and bring the clinician to perform other diagnostic imaging tests or to proceed with RRA and ptWBS without uncertainty. However, the postthyroidectomy serum Tg was not suspicious in the other 4 cases (1 bone and the other lung metastasis, 1 mediastinal, and 1 laterocervical lymph node metastasis). It is likely that these cases would have had a different outcome if the ptWBS had not been performed. In fact, most of them were finally cured with the appropriate therapeutic strategies [23] , and we cannot determine if this would have happened if the diagnosis of the metastatic lesions had come later.
In conclusion, we found that the diagnostic role of ptWBS was significant and relevant for the therapeutic strategies only in 1.1% of our LR and IR patients prepared with LT4 withdrawal, similarly to the series of LR and IR patients prepared with rhTSH (1.3%). This finding confirms that the sensitivity of the ptWBS was not affected by the type of preparation (i.e., LT4 withdrawal vs. rhTSH).
We found no differences according to the initial level of risk since the metastatic cases represented 0.87% of the LR and 1.5% of the IR patients. As previously stated, we do not know what would have happened to these patients if RRA had not been performed. However, 30% of them would not have been overlooked. In fact, they would have been treated with RRA anyway because of the elevated serum Tg levels at the postoperative control, confirming the relevance of serum Tg at this time of the follow-up of DTC patients [18] . Similarly, the 10 cases with metastatic lymph node at neck US would have been treated anyway because of this finding. The cost-effectiveness of performing RRA and ptWBS in all LR and IR patients, either after LT4 withdrawal or rhTSH, to find 1-2% of the cases with distant metastases remains to be established but is rather unlikely.
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